Simultaneous Results

Procleix Assays within the Ultrio family combine the early detection capabilities of Nucleic Acid Testing (NAT) with single-tube TMA technology.

  • Deliver simultaneous results for HIV, HCV, and HBV

Reduce Risk

The Procleix Parvo/HAV assay reduces the risk of parvovirus B19 and hepatitis A virus transmission in plasma-derived products while optimizing your NAT testing efficiency.

  • Provides operator-assigned parvovirus B19 quantitative cut-off
  • Enables simultaneous quantification and qualitative detection of parvovirus B19 and HAV

Highly Sensitive Detection

  • The qualitative Procleix HEV assay detects all four genotypes of the hepatitis E virus
  • The Procleix WNV assay is highly sensitive, CE-mark certified and FDA-approved, with a limit of detection that is better than 10 copies/mL*

    * Based on probit analysis.

Procleix Assays

Procleix Ultrio Elite
Procleix Ultrio Elite
Procleix Ultrio Plus
Procleix Ultrio Plus
Procleix Ultrio Assays
Procleix Ultrio Assays
Procleix Parvo/HAV Assay
Procleix Parvo/HAV Assay
Procleix HEV Assay
Procleix HEV Assay

This information is intended for physicians and healthcare professionals only.

Product registration and availability vary by country. For more information on product availability, please contact us here.